01866nai a2200433 i 4500001001300000003000600013005001700019006001900036007001500055008004100070010001500111040003400126042000800160043001200168074002300180086002300203100002300226245017300249250004200422264006500464300002300529336000800552337001600560338001900576490005500595500014400650500005500794504004800849588009200897700002000989710005801009773012901067830002701196856004001223650003701263650004201300650004001342650005001382on1135463384OCoLC20200220142432.0m     o  d f      cr mn|||||||||200109c20189999dcu x w obb  f0    2eng c  a2020230703  aPUCPRbengerdaepncGPOdMvI  apcc  an-us---  a0807-A-07 (online)0 aLC 14.23:RL 34101/1 aAustin, D. Andrew,10aDoes price transparency improve market efficiency?  :bimplications of empirical evidence in other markets for the health sector  /cD. Andrew Austin, Jane G. Gravelle.  a[Library of Congress public edition]. 1a[Washington, D.C.] :bCongressional Research Service,c2018-  a1 online resource.  btxt  bc2rdamedia  bcr2rdacarrier1 aReport / Congressional Research Service ;vRL34101  aThe CRS report home page provides access to all versions published since 2018 in accordance with P.L. 115-141; earliest version dated 2008.  aGPO Cataloging Record Distribution Program (CRDP).  aReport includes bibliographical references.  aDescription based on contents viewed on Dec. 31, 2019; title from CRS report home page.1 aGravelle, Jane,2 aLibrary of Congress.bCongressional Research Service,08iContained in (work):tCRS reports (Library of Congress. Congressional Research Service)w(DLC) 2018231131w(OCoLC)1052784408 0aCRS report ;vRL34101.40uhttps://purl.fdlp.gov/GPO/gpo130191 0aPrice regulationzUnited States. 0aMedical care, Cost ofzUnited States. 0aDrugszUnited StatesxCost control. 0aDrugsxPricesxHealth aspectszUnited States.